GLP-1 Diabetes Drugs Show Potential as Broad Anticancer Agents

Emerging evidence suggests GLP-1 receptor agonists, drugs commonly used to treat diabetes and obesity, may have beneficial effects across multiple cancer types, indicating potential for drug repurposing; further clinical research is needed to confirm efficacy, optimal dosing, and safety.